bmiMD
Clinical weight-loss telehealth via Semaglutide + Tirzepatide compounds - same active ingredients as Wegovy and Mounjaro at telehealth pricing.
Compounded Semaglutide ($289/mo) and Tirzepatide ($349/mo) via US-licensed telehealth - same active molecules as Wegovy and Zepbound at 5-7x lower cost than uninsured retail ($1,400-1,800/mo brand pricing). 60K+ active members, 4.9-star rating, prescription issued during onboarding.
bmiMD entered the GLP-1 telehealth segment in 2023 with a clear positioning: same Semaglutide and Tirzepatide compounds as Wegovy and Mounjaro, delivered via compounding-pharmacy partnerships at meaningfully lower monthly cost. The clinical efficacy of the underlying compounds is the same - what differs is sourcing (compounding pharmacies vs branded retail), price ($199-499/mo vs $1,000+/mo retail), and convenience (telehealth vs in-clinic).
For longevity buyers, GLP-1 fits a narrow but increasingly important segment: metabolic-health work where weight is a significant lever and dietary intervention alone hasn't closed the gap. The 2024-2026 longevity research has rapidly elevated GLP-1s from pure-weight-loss to metabolic-aging interventions, with cardiovascular + cognitive + inflammation benefits documented across multiple studies.
The competitive frame: bmiMD sits alongside Hims, Henry Meds, ShedRX, and Levity in the GLP-1 telehealth segment. The differentiator is pricing transparency + clinical-MD oversight + program structure (titration support, side-effect coaching, monthly check-ins). The honest take: if you want GLP-1 access without paying brand-name retail, bmiMD is one of 4-5 credible options in the category.
Buyers ready for GLP-1 medical intervention who want telehealth access at meaningfully lower cost than retail Wegovy / Mounjaro, with included physician oversight and titration support.
You're unsure GLP-1 is the right intervention - start with diet + exercise + lab work first. Or you have insurance coverage for retail Wegovy / Mounjaro (run those through insurance instead).
Specifications
Most often compared with
Featured in these curated stacks
We’ve included this product in 2 editorial bundles - groupings of 4-7 items that work as a system.
Where this fits
bmiMD GLP-1 Telehealth (Semaglutide / Tirzepatide) cross-shops across several editorial surfaces - the full brand catalog, the buyer-intent tags this item carries, the price band it qualifies for, and any execution playbook that uses it.
bmiMD GLP-1 Telehealth (Semaglutide / Tirzepatide) - buyer FAQ
Is bmiMD's compounded Semaglutide the same as Wegovy or Ozempic?
The active ingredient is identical - Semaglutide. The difference is the manufacturer: Wegovy and Ozempic are produced by Novo Nordisk under brand-name FDA approval; bmiMD's version is produced by FDA-licensed compounding pharmacies under 503A patient-specific compounding regulations. Same molecule, same mechanism, same clinical effects. Pricing is the main difference: bmiMD at $289/mo vs $1,400-1,800/mo brand without insurance.
How much does bmiMD cost vs brand-name Wegovy or Zepbound?
bmiMD: Semaglutide $289/mo, Tirzepatide $349/mo. Brand without insurance: Wegovy/Ozempic $1,400-1,800/mo, Zepbound/Mounjaro $1,500-1,800/mo. Brand WITH insurance coverage: typically $25-100/mo co-pay. For uninsured buyers, bmiMD is 5-7x cheaper than brand. For insured buyers with coverage, brand is cheaper through your existing physician.
Do I need a prescription before signing up with bmiMD?
No. The bmiMD flow includes the consultation that produces the prescription - 5-minute online questionnaire, video or async consult with a US-licensed physician, and lab work via in-network draw or mail-in panel. The prescription is issued during this onboarding if you medically qualify. You don't bring an existing prescription; you go through the bmiMD physician.
Is bmiMD legal in all US states?
bmiMD operates under US compounded-pharmacy regulations and works in most US states, but state-by-state coverage varies for compounded telehealth GLP-1. The bmiMD intake form filters by state during onboarding - verify your state is covered before completing payment. The compounded telehealth space has been more regulatory-active in 2024-2025 so state availability shifts.
What's the difference between Semaglutide and Tirzepatide via bmiMD?
Semaglutide ($289/mo at bmiMD) is the active in Wegovy/Ozempic - single-mechanism GLP-1 receptor agonist. Tirzepatide ($349/mo at bmiMD) is the active in Zepbound/Mounjaro - dual-mechanism GLP-1 + GIP receptor agonist, generally producing larger weight changes in trials but at higher cost. For first-time GLP-1 users, Semaglutide is the conservative starting point; for buyers prioritizing maximum effect, Tirzepatide is the upgrade tier.